AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY

摘要

Disclosed are aminotetraline derivatives of formula (I), salts thereof, and methods for their preparation. Specific examples of compounds of formula (I) include: [7-(2-tert-Butoxycarbonylamino-ethoxy)-1-(3,4-dichloro-benzyl)-1,2,3,4-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester; Pyrrolidine-3-sulfonic acid { 2-[7-amino-8-(3,4-dichloro-benzyl)-5,6,7,8-tetrahydronaphthalen-2-yloxy]-ethyl} amide; N-{ [7-Amino-8-(3,4-dichlorobenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl]methyl} -3-fluoropropane-1-sulfonamide; Propane-1-sulfonic acid { 2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2-yloxy]-ethyl)-amide; and 2,5-Dimethyl-thiophene-3-sulfonic acid { 2-[7-amino-8-(3-chloro-benzyl)-5,6,7,8-tetrahydro-naphthalen-2-yloxy]-ethyl} -amide. Aminotetralin compounds of formula (I) are inhibitors of the glycine transporter GlyT1. The compounds can treat neurologic or psychiatric disorders and pain, particularly those associated with glycinergic or glutamatergic neurotransmission dysfunction such as dementia, cognitive impairment and attention deficit disorder.